131 related articles for article (PubMed ID: 25998298)
1. Erratum. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care 2015;38:384-393.
DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
Diabetes Care; 2015 Jun; 38(6):1173. PubMed ID: 25998298
[No Abstract] [Full Text] [Related]
2. Erratum. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015;38:394-402.
Lewin A; DeFronzo RA; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
Diabetes Care; 2015 Jun; 38(6):1173. PubMed ID: 25998299
[No Abstract] [Full Text] [Related]
3. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.
Koliaki C; Doupis J
Adv Ther; 2012 Dec; 29(12):993-1004. PubMed ID: 23184570
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of Jentadueto® (linagliptin plus metformin).
Scheen AJ
Expert Opin Drug Saf; 2013 Mar; 12(2):275-89. PubMed ID: 23421949
[TBL] [Abstract][Full Text] [Related]
9. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
[TBL] [Abstract][Full Text] [Related]
11. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.
Haak T
Adv Ther; 2012 Dec; 29(12):1005-15. PubMed ID: 23212658
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
Gomis R; Owens DR; Taskinen MR; Del Prato S; Patel S; Pivovarova A; Schlosser A; Woerle HJ
Int J Clin Pract; 2012 Aug; 66(8):731-740. PubMed ID: 22691164
[TBL] [Abstract][Full Text] [Related]
13. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
14. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
[TBL] [Abstract][Full Text] [Related]
16. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
[TBL] [Abstract][Full Text] [Related]
17. [Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data].
Galeone F; Fiore G; Arcangeli A; Mannucci E
Minerva Endocrinol; 1998 Sep; 23(3):71-5. PubMed ID: 10063324
[TBL] [Abstract][Full Text] [Related]
18. Erratum: The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum.
Medicine (Baltimore); 2016 Oct; 95(42):e18ea. PubMed ID: 31265657
[TBL] [Abstract][Full Text] [Related]
19. Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes.
Raedler LA
Am Health Drug Benefits; 2015 Mar; 8(Spec Feature):171-5. PubMed ID: 26629285
[No Abstract] [Full Text] [Related]
20. Erratum. Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE. Diabetes Care 2024;47:556-561.
Riddle MC
Diabetes Care; 2024 Jun; 47(6):1099. PubMed ID: 38564373
[No Abstract] [Full Text] [Related]
[Next] [New Search]
